Lead Product(s) : NBI-1117568
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Neurocrine Biosciences
Deal Size : $2,700.0 million
Deal Type : Collaboration
Nxera to Receive US$15 Million Following Dosing of First Patient in Phase 3
Details : NBI-1117568 is the first and only investigational oral muscarinic M4 selective orthosteric agonist in clinical development as a potential treatment for schizophrenia.
Product Name : NBI-1117568
Product Type : Other Small Molecule
Upfront Cash : $100.0 million
June 02, 2025
Lead Product(s) : NBI-1117568
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Neurocrine Biosciences
Deal Size : $2,700.0 million
Deal Type : Collaboration
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Bain Capital
Deal Size : $3,300.0 million
Deal Type : Acquisition
Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation
Details : Tanabe Pharma will continue to build on its legacy of medical innovation in internal product development including MT-210 (roluperidone), being developed for schizophrenia.
Product Name : MT-210
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 07, 2025
Lead Product(s) : Roluperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Bain Capital
Deal Size : $3,300.0 million
Deal Type : Acquisition
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole and Sertraline Combination
Details : Rexulti (brexpiprazole) 5-HT2A receptor, is being evaluated in combination with sertraline in late-stage clinical trials with adult patients for the treatment of post-traumatic stress disorder.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole
Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder.
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka and Lundbeck Announce FDA Acceptance for Brexpiprazole in PTSD Treatment
Details : Rexulti (brexpiprazole) is an partial agonist of serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2024
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brilaroxazine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Agreement
RevolKa enters master service agreement with Daiichi Sankyo
Details : RevolKa will create and deliver highly functional proteins, in collaboration with Daiichi by using its proprietary protein engineering platform technology, called aiProtein for RP5063 (brilaroxazine).
Product Name : RP5063
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 29, 2024
Lead Product(s) : Brilaroxazine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : $30.0 million
Deal Type : Licensing Agreement
Otsuka and Sumitomo Revise License Agreement
Details : Under the license agreement, Otsuka holds exclusive rights to develop, manufacture, and commercialize SEP-363856 (ulotaront), TAAR1 agonist. It is being evaluated with the patient for Schizophrenia.
Product Name : SEP-363856
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 15, 2024
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : $30.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Centanafadine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Centanafadine Capsule is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor, which is investigated for the treatment of Attention-Deficit/Hyperactivity Disorder.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2023
Lead Product(s) : Centanafadine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEP-363856 (ulotaront) is a TAAR1 agonist with 5-HT1A agonist activity, is currently under investigation for the treatment of schizophrenia, generalized anxiety disorder and the adjunctive treatment of MDD with additional indications under consideration.
Product Name : SEP-363856
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2023
Lead Product(s) : Ulotaront
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Product Name : Rexulti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2023
Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable